Globus Medical (GMED): Assessing Valuation After a 60% Three-Month Share Price Surge
Globus Medical (GMED) has quietly outperformed many medical device peers over the past 3 months, with shares climbing roughly 60%, prompting investors to revisit what is driving the stock’s renewed momentum.
See our latest analysis for Globus Medical.
Zooming out, the recent 60.49% 3 month share price return compares with a more modest 5.94% one year total shareholder return. This suggests momentum has only really accelerated lately as investors warm to its growth profile and robotics portfolio.
If Globus Medical’s run has you rethinking the healthcare space, this could be a good moment to scout other ideas with our curated list of healthcare stocks.
With shares now near record highs yet still trading below analyst targets and some intrinsic value estimates, the key question is whether Globus Medical remains undervalued or if markets are already pricing in its future growth.
Most Popular Narrative Narrative: 7.6% Undervalued
Globus Medical's most followed valuation narrative pegs fair value at about $95.70 per share, above the recent $88.43 close, framing a modest discount rooted in execution strength.
Successful integration and synergy capture from the NuVasive and Nevro acquisitions are providing opportunities for increased cross-selling, cost efficiencies, and realization of deferred tax assets, which are expected to drive margin expansion, boost earnings, and enhance recurring cash flows in upcoming years.
Curious how this story turns integration complexity into a higher valuation? The narrative leans on ambitious revenue compounding, higher margins, and a future earnings multiple usually reserved for faster growing sectors. Want to see which specific growth and profitability assumptions are most influential in that fair value math? Read on and test whether those projections line up with your own views.
Result: Fair Value of $95.70 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, stretched sales cycles for robotics and lingering integration challenges at Nevro and NuVasive could derail the margin and earnings ramp that underpins that valuation.
Find out about the key risks to this Globus Medical narrative.
Build Your Own Globus Medical Narrative
If you would rather question these assumptions and dig into the numbers yourself, you can quickly build a customized view and narrative in just minutes, Do it your way.
A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Globus Medical.
Looking for more investment ideas?
Before you move on, consider your next moves with fresh opportunities surfaced by the Simply Wall St Screener, so you do not leave potential returns on the table.
- Explore mispriced opportunities by targeting companies trading below their cash flow potential through these 901 undervalued stocks based on cash flows.
- Focus on early stage innovators shaping the future of intelligence with these 24 AI penny stocks.
- Review reliable payers using these 10 dividend stocks with yields > 3%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com